We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Behavioral Therapy Development for Methamphetamine Abusers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00249678
Recruitment Status : Suspended
First Posted : November 7, 2005
Last Update Posted : June 3, 2013
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Condition or disease Intervention/treatment Phase
The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings. Behavioral: Behavior Therapy Phase 2

Study Design

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 50 participants
Primary Purpose: Treatment
Official Title: Behavioral Therapy Development for Methamphetamine Abuse
Study Start Date : September 2004
Estimated Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Methamphetamine
U.S. FDA Resources

Arms and Interventions

Outcome Measures

Primary Outcome Measures :
  1. Craving
  2. Medication compliance
  3. Addiction severity
  4. Psychiatric interview
  5. Sex-risk behavior

Secondary Outcome Measures :
  1. Depression
  2. Quality of Life

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65
  2. Willing to give informed consent and comply with study procedures;
  3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;
  4. Diagnosed with current methamphetamine abuse as determined by MINI; and
  5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

  1. Unwilling to give, or withdrawal of, informed consent;
  2. Inability to understand nature of study;
  3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);
  4. Current suicidal ideation or suicide attempt within the past 3 months; and
  5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.
  6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00249678

United States, California
UCLA Medical Center
Los Angeles, California, United States, 90024
UCLA, Integrated Substance Abuse Programs
Los Angeles, California, United States, 90024
Los Angeles, California, United States, 90035
Sponsors and Collaborators
University of California, Los Angeles
National Institute on Drug Abuse (NIDA)
Principal Investigator: James Peck, Other University of California, Los Angeles
More Information

Responsible Party: Steve Shoptaw, Professor, University of California, Los Angeles
ClinicalTrials.gov Identifier: NCT00249678     History of Changes
Other Study ID Numbers: NIDA-18075-1
R21DA018075 ( U.S. NIH Grant/Contract )
First Posted: November 7, 2005    Key Record Dates
Last Update Posted: June 3, 2013
Last Verified: May 2013

Keywords provided by Steve Shoptaw, University of California, Los Angeles:
Behavior Therapy

Additional relevant MeSH terms:
Central Nervous System Stimulants
Physiological Effects of Drugs
Autonomic Agents
Peripheral Nervous System Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Agents
Adrenergic Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Dopamine Uptake Inhibitors